1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Bioventus Inc.
  6. Summary
    BVS   US09075A1088

BIOVENTUS INC.

(BVS)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
8.550 USD   -3.61%
08/03Bioventus Receives FDA Marketing Clearance for neXus SonaStar Elite Device
MT
08/03Bioventus Receives FDA 510(k) Clearance for SonaStar Elite  
AQ
08/03Bioventus Receives FDA 510(k) Clearance for SonaStar Elite
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/02/2022 08/03/2022 08/04/2022 08/05/2022 08/08/2022 Date
8.7(c) 8.73(c) 8.75(c) 8.87(c) 8.55(c) Last
78 129 86 145 47 712 62 425 123 559 Volume
+6.62% +0.34% +0.23% +1.37% -3.61% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 552 M - -
Net income 2022 68,0 M - -
Net Debt 2022 228 M - -
P/E ratio 2022 342x
Yield 2022 -
Sales 2023 611 M - -
Net income 2023 37,8 M - -
Net Debt 2023 239 M - -
P/E ratio 2023 24,1x
Yield 2023 -
Capitalization 525 M 525 M -
EV / Sales 2022 1,36x
EV / Sales 2023 1,25x
Nbr of Employees 1 150
Free-Float 67,0%
More Financials
Company
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body's natural healing process. Its portfolio of products is grouped into three verticals: Pain Treatments, Surgical Solutions and Restorative Therapies. Its Pain Treatments consist of non-surgical joint pain injection therapies... 
More about the company
Ratings of Bioventus Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about BIOVENTUS INC.
08/03Bioventus Receives FDA Marketing Clearance for neXus SonaStar Elite Device
MT
08/03Bioventus Receives FDA 510(k) Clearance for SonaStar Elite  
AQ
08/03Bioventus Receives FDA 510(k) Clearance for SonaStar Elite
CI
07/26Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, ..
AQ
07/12Bioventus Unveils $80 Million Loan Facility Maturing 2026
MT
07/12BIOVENTUS INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or ..
AQ
07/12Bioventus Completes Acquisition of Medical Device Firm CartiHeal
MT
07/12BIOVENTUS : Completes CartiHeal Acquisition
PU
07/12Bioventus Inc. completes the acquisition of Cartiheal Ltd for $450 million.
CI
06/29Bioventus Chief Commercial Officer John Nosenzo to Retire in October
MT
06/29BIOVENTUS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/29Bioventus Inc. Announces Executive Changes
CI
06/24BIOVENTUS INC.(NASDAQGS : BVS) dropped from Russell 2500 Growth Index
CI
06/24BIOVENTUS INC.(NASDAQGS : BVS) dropped from Russell Microcap Growth Index
CI
06/24BIOVENTUS INC.(NASDAQGS : BVS) dropped from Russell 3000E Growth Index
CI
More news
News in other languages on BIOVENTUS INC.
08/03Bioventus reçoit l'autorisation de commercialisation de la FDA pour le dispositif neXus..
08/03Bioventus reçoit l'autorisation 510(k) de la FDA pour SonaStar Elite
07/12Bioventus dévoile une facilité de prêt de 80 millions de dollars arrivant à échéance en..
07/12Bioventus conclut l'acquisition de la société de dispositifs médicaux CartiHeal
07/12BIOVENTUS INC. (NASDAQGS : BVS) conclut l'acquisition de Cartiheal Ltd pour 450 millions d..
More news
Analyst Recommendations on BIOVENTUS INC.
More recommendations
Chart BIOVENTUS INC.
Duration : Period :
Bioventus Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,55 $
Average target price 19,00 $
Spread / Average Target 122%
EPS Revisions
Managers and Directors
Kenneth Michael Reali Chief Executive Officer & Director
Mark Singleton Chief Financial & Accounting Officer, Senior VP
William A. Hawkins Chairman
Alessandra Pavesio Chief Science Officer & Senior Vice President
Peter J. Shaw Chief Medical Officer & VP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BIOVENTUS INC.-40.99%544
MASIMO CORPORATION-47.59%8 518
SHOCKWAVE MEDICAL, INC.25.13%7 987
NOVOCURE LIMITED3.41%7 920
PENUMBRA, INC.-41.94%6 321
GETINGE AB-44.19%5 869